Richardson Family Office Invests in Singapore AI Healthtech Startup Injewelme

Key Takeaways

• Richardson family office commits $185k to impact platform Co-Axis.
• $1.2 million round backs injewelme’s AI vitals monitoring tech.
• DeepHealthVision achieves 95% accuracy in real‑world Singapore pilots.
• Funding targets product upgrades and expansion across Southeast Asia.

Pulse Analysis

Injewelme’s entry into the capital markets underscores a broader shift toward AI‑enabled, contactless health monitoring. Traditional vital‑sign measurement relies on wearables or clinical equipment, limiting accessibility in low‑resource settings. By leveraging a standard camera and remote photoplethysmography, DeepHealthVision can deliver rapid, accurate readings, positioning the startup to meet rising demand from telehealth providers, insurers, and occupational safety programs across the region.

The Richardson family office’s participation reflects an emerging trend of legacy wealth vehicles allocating capital to high‑impact, technology‑driven ventures. With a portfolio spanning real estate, logistics, and growth‑stage tech, Richardson’s $1.2 million injection—paired with a $185,000 pledge to Co‑Axis—signals confidence in the scalability of AI health solutions and a strategic pivot toward socially responsible investments. This aligns with Temasek Trust’s C3H vehicle, which seeks to blend financial returns with climate and health outcomes.

Looking ahead, the funding will fuel injewelme’s product roadmap, notably adding heat‑stress detection—a critical feature for workers in tropical climates. Expansion plans target Southeast Asian markets where healthcare infrastructure varies widely, offering a low‑cost alternative to traditional monitoring. Successful deployment could catalyze broader adoption of AI healthtech, prompting further interest from insurers and corporate wellness programs, and potentially reshaping how vital data is captured in emerging economies.